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Introduction. The safety of vitamin K antagonists (VKA) use can be compromised by many popular herbal supplements taken by
individuals. The literature reports that 30% of warfarin-treated patients self-medicates with herbs. Possible interactions represent
an health risk. We aimed to identify all herbs-oral anticoagulants interactions collected in the Italian database of suspected adverse
reactions to “natural health” products. Methods. The Italian database of spontaneous reports of suspected adverse reactions to
natural products was analyzed to address herb-VKAs interactions. Results. From 2002 to 2009, we identified 12 reports with 7
cases of INR reduction in patients treated with warfarin (n = 3) and acenocoumarol (n = 4), and 5 cases of INR increase (all
warfarin associated). It was reported 8 different herbal products as possibly interacting. Discussion. Our study confirms the risk of
interactions, highlighting the difficulty to characterize them and their mechanisms and, finally, prevent their onset. The reported
data underline the urgent need of healthcare providers being aware of the possible interaction between natural products and VKA,
also because of the critical clinical conditions affecting patients. This is the first step to have the best approach to understand
possible INR alterations linked to herb-VKA interaction and to rightly educate patients in treatment with VKA.
1. Introduction
Warfarin and other vitamin k antagonists (VKAs) are widely
used as oral anticoagulants, for treatment or prevention of
thromboembolism, in particular, in case of atrial fibrillation.
Oral anticoagulants have a narrow therapeutic index; there-
fore, even small changes in plasma concentration could lead
to marked alterations in therapeutic effect and/or toxicity.
Despite the possibility of monitoring the anticoagulation
status by measuring prothrombin time (PT) expressed as
international normalised ratio (INR), the management of
therapy is challenging because those parameters usually show
unpredictable inter- and intraindividual variability. Gender,
age, ethnicity, and vitamin K intake (foods and herbs)
can contribute to this instability, by pharmacokinetic and
pharmacodynamic interactions. Genetic polymorphisms in
vitamin K metabolizing enzymes also correlate with dose
requirements. Case reports and case series represent the
bulk of evidence regarding herb-warfarin interactions [1, 2],
even if most reports do not deal with mechanisms, being
“theoretical speculations” the sole bases for the analysis
of potential interactions. Despite these concerns, several
surveys reported that about 30% of warfarin-treated patients
self-medicate with herbal remedies [1]. Use of herbal drugs
and nonconventional medicine in Italy is quite diffuse, with
almost 9 million people (13.6% of the Italian population)
using at least one unconventional therapy during the year
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2005; herbal medicine in particular is used by 3.7% of Italian
population [3].
In this frame, since the Italian Pharmacovigilance System
(Italian Medicines Agency—AIFA) only collects reports for
registered drugs, the Italian National Institute of Health
(Istituto Superiore di Sanita`—ISS) sets up a specific adverse
reaction reporting system for natural health products, by
means of which from April 2002 to December 2009,
379 spontaneous reports of suspected adverse reactions to
natural health products were collected. In the first phase
of the surveillance, reports were sent mainly from few
clinical centres in northern Italy, while the number of
different reporters increased, including hospital doctors,
general practitioners, and pharmacists from most Italian
regions.
2. Methods
In the present study, the Italian database of spontaneous
reports of suspected adverse reactions to natural products
was analyzed to address herb-VKAs interactions. Patients,
showing INR modifications after herbal drugs assumption,
were included in the analysis only if they were previously
stably anticoagulated (>65%of time in therapeutic range and
at least 3 consecutive INR evaluation in therapeutic range
before the reported case).
The probability that the adverse events were the result of
drug interaction was assessed in accordance to a modified
Naranjo scale, the Drug Interaction Probability Scale specif-
ically adapted for warfarin-dietary supplements interactions
[1]. Factors interfering with VKAs (illnesses, dietary vitamin
K intake changes) were excluded.
3. Results
From 2002 to 2009, we identified 12 reports with 7 cases of
INR reduction in patients treated with warfarin (n = 3) and
acenocoumarol (n = 4), and 5 cases of INR increase (all
warfarin associated).
3.1. Reduction of Anticoagulant Effect. Seven cases showed
a significant reduction of INR (Table 1), discovered after
routine coagulation blood test 4 days to 1 month after the
start of herbal preparations consumption. Patients were in
chronic therapy with warfarin (n = 3) or acenocoumarol
(n = 4). Partial or complete normalization of INR was
obtained after herbal preparations withdrawal (dechallenge)
and increase in VKAs dosage. Six events were assessed as
“possible” and one as “probable.”
In one case, the INR reduction occurred with concomi-
tant intake of warfarin and home-made aloe preparation.
Although in the medical literature no evidence is reported
of reduction of anticoagulant efficacy due to specific aloe-
warfarin interactions, it is known that anthranoid plants
(such aloe leafs) can influence the absorption of drugs by
accelerating the gastrointestinal emptying, thereby decreas-
ing their bioavailability. It has been reported that aloe exerts
antiplatelet effects, due to its salicylates content: a case report
describes a massive bleeding due to the interaction between
aloe and sevoflurane, possibly due to the pharmacodynamic
antiplatelet effects of these two agents [4].
We also reported the possible interaction between
acenocoumarol and red ginseng. INR decline associated
with coadministration of ginseng and warfarin has been
reported [5]. Themechanism of ginseng-anticoagulant drugs
interaction has not been elucidated, it could be that ginseng
reduces the anticoagulant effect of warfarin through the
induction of CYP450 liver enzymes. In a randomised, double
blind, placebo controlled trial, after 2 weeks of ginseng
administration, healthy subjects showed a statistically sig-
nificant reduction of peak INR, warfarin peak plasma level
and area under the curve in comparison with the placebo
group [6]. However, the effect of ginseng on CYP450 is still
controversial.
A reduction of anticoagulant effect was observed in a
patient taking a fermented preparation made from yeast
fermentation of papaya and in a patient taking papaya
extract. However, papaya assumption has been associated
with the increase of warfarin effect through the inhibition of
platelet aggregation [7]. The fermentated product has a high
content in β-glucans, which may be involved in the reduction
of the anticoagulant effect of warfarin since they could
promote coagulation, interacting with its extrinsic pathway,
probably by inducing monocyte tissue factor expression in
human whole blood [8]. For the other case, we have not an
explanation of the effect produced.
In one case, INR reduction occurred after assumption of
warfarin and bilberry concentrate juice. We found no similar
reports in the literature. The reduction of warfarin activity
is unexpected since, the bilberry anthocyanosides, retaining
antiplatelet properties, should increase the bleeding risk
when co-administered with anticoagulant and antiplatelet
drugs [9]. The interaction mechanism is unknown. Twelve
cases of possible interaction between cranberry and warfarin
have been reported to the Committee on Safety of Medicine
in the UK, including eight cases with increased INR and/or
bleeding episodes, three cases of unstable INR, and one
case of decreased INR. INR increase in concomitance with
cranberry juice intake has been described [10] with multiple
possible mechanisms of action. These reports suggest that
patients on warfarin therapy should be discouraged from
drinking juice of plants belonging to the Vaccinium Species.
One case of INR reduction following the assumption of
dietary supplement containing several vitamins (C, E, A)
and fish oil was reported. According to the literature, its
components could afford an increase of INR instead of a
reduction. In fact, vitamin A in high doses was reported to
prolong prothrombin time and induce bleeding in subjects
treated with warfarin, although this evidence is based on
few case reports and with un unclear mechanism of action
[11]. The same is for vitamin E [11] and fish oil, reported
to affect platelet aggregation and/or vitamin K-dependent
coagulation factors [12]. Because of our case and the scarcity
of evidence for INR-increase, further investigations should
be conducted.
Finally, we report a case of INR reduction after oral
intake of a dietary supplement containing green tea and
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Table 1: Reports of INR reduction associated with use of natural remedies.
Sex, age
(years)
Product, dosage, and indication
Concomitant
medications and notes
Adverse drug reaction, time to
onset, and Naranjo score
Action taken and outcome
F, 45
Camellia sinensis, Malva sylvestris,
Elettaria cardamomum, Hibiscus
sabdariffa (THERMOJETICS,
Herbalife International of America,
Inc Los Angeles, CA), 3 g/day; weight
loss diet
Acenocoumarol 14mg/w
(since 10 years)
Reduction of anticoagulant
therapy efficacy INR 1.4; 16
days; Possible [4]
Herbal drugs withdrawn,
Acenocoumarol dosage
increase (16mg/w);
completely recovered
F, 70
Aloe barbadensis, honey, alcohol
beverage, herbal liquid home-made
preparation, 3 spoons/day;
constipation
Warfarin 5mg/w (since
10 years)
Reduction of anticoagulant
therapy efficacy INR 1.42; 2
weeks; Possible [3]
Herbal drug withdrawn,
warfarin dosage increase
(6.25mg/w); completely
recovered
F, 81
Panax Ginseng (Red Ginseng), dosage
not reported; tiredness and dizziness
Acenocoumarol 7mg/w
Reduction of anticoagulant
therapy efficacy INR 0.99;
Possible [4]
Herbal drugs withdrawn,
Acenocoumarol dosage
increase (08mg/w);
completely recovered
M, 70
Fermented Papaya Preparation
(IMMUN’AGE FPP, Osato
international, Gifu, Japan), 3 g/day
orally; ageing prevention
Warfarin 25mg/w (since
9 years)
Reduction of anticoagulant
therapy efficacy INR 1.64; 1
month; Probable [8]
Herbal drug withdrawn,
warfarin dosage increase
(27.5mg/w); completely
recovered
F, 80
Vaccinium myrtillus (BILBERRY
JUICE, Sottobosco Paoli, Civezzano,
Italy), 200ml/day; indication not
reported
Warfarin 27.5mg/w
(since 1.5 year)
Reduction of anticoagulant
therapy efficacy INR 1.6; 4
days; Possible [4]
Herbal drug withdrawn,
warfarin dosage increase
(32.5mg/w); completely
recovered
F, 63
Spirea ulmaria, Taraxacum officinale,
Sambucus nigra, Betula alba, Urtica
dioica, Cynara scolymus, Amarena,
Ttriticum repens, Tilia cordata
(AFFILINE, Nahrin AG, Saren,
Switzerland), 1 spoon/day and
Spirulina maxima, Urtica Dioica,
Papaya extract (LINPHACELL Nahrin
AG, Saren, Switzerland), 4 tablets/day;
weight loss diet
Acenocoumarol 20mg/w
(since 2 years)
Reduction of anticoagulant
therapy efficacy INR 1.37; 1
month; Possible [2]
Herbal drugs withdrawn,
Acenocoumarol dosage
increase (22mg/w);
improvement
M, 79
vitamins (C,E), fish oil, lutein,
zeaxantin, minerals (PRESERVISION
3, Bausch & Lomb incorporated
Rochester, NY), 1 capsule/day;
macular degeneration
Acenocoumarol 11mg/w
(since 15 years)
Reduction of anticoagulant
therapy efficacy INR 1.50; 6
days; Possible [3]
Supplement withdrawn,
Acenocoumarol dosage
increase (12mg/w);
improvement
other herbal extracts. Green tea contains vitamin K, which
may directly antagonize the anticoagulant effect of coumarin
drugs. Brewed green tea contains low amounts of vitamin K
[13]; therefore, large quantities of brewed green tea would be
necessary to have a significant changes in INR. However, the
possible inhibitory effect of green tea on warfarin should be
kept in mind.
3.2. Increase of Anticoagulant Effect. Many herbs, such as Dan
Shen and Dang Gui, have been reported to enhance war-
farin anticoagulation, as documented by the INR increase.
Compounds like licorice, passionflower, and arnica contain
coumarin derivates. Other compounds, including garlic
and ginkgo, increase the bleeding risk associated with
coumarin inhibiting platelet aggregation [1]. We report 5
cases of INR increase in warfarin-treated patients 10–30 days
after consumption of arnica- or boswellia-based products
(Table 2).
One patient showed the INR elevation after 10 days of
assumption of arnica tablets for myalgia. Complete recovery
was achieved after dechallenge.
Another patient had a serious adverse event, with
elevation of INR after 1 month of arnica homeopathic cream
application for myalgia. After dechallenge and vitamin-
K treatment, INR returned in therapeutic range. Causal
relationship was assessed as “possible” for both events. In the
second case reported, we hypothesize that systemic adsorp-
tion from the topic application site has occurred, allowing
coumarin derivates contained in Arnica, as scopoletin and
unbelliferone [11], to induce over-anticoagulation.
In two other cases, INR increase occurred with con-
comitant intake of warfarin and Boswellia serrata. In both
cases, complete recovery was achieved after dechallenge,
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Table 2: Reports of INR increase associated with use of natural remedies.
Sex, age
(years)
Product, dosage, and indication
Concomitant
medications and notes
Adverse drug reaction, time
to onset, and Naranjo score
Action taken and
outcome
M, 77
Arnica compositum (ARNICA CREAM
HEEL, Heel Inc., Albuquerque, NM),
dosage not reported; myalgia
Warfarin 35mg/w
Overanticoagulation INR
10.6; 1 month; Possible [4]
Konakion
administration; herbal
drug withdrawn;
completely recovered
F, 42
Arnica compositum; calendula;
Hamamelis; Millefolium; belladonna;
Aconitum; mercurius solubilis
hanemanni; hepar sulfuris;Bellis
perennis; Echinacea; Hypericum
(ARNICA CPR HEEL, Heel Inc.,
Albuquerque, NM), 2 tablets/day;
myalgia
Warfarin
Overanticoagulation;
Possible [4]
Unknown
F, 73
Boswellia serrata dry extract (D E)
95%, 1500mg/day; osteoarthritis
Warfarin
Overanticoagulation
increase of INR; 10 days;
Probable [6]
Herbal drug withdrawn;
completely recovered
F, 64
Boswellia serrata DE 95%,
1200mg/day; osteoarthritis
Warfarin
Overanticoagulation
increase of INR; 10 days;
Probable [6]
Herbal drug withdrawn;
completely recovered
M, 61
Passiflora spp, Foenicum vulgare,
Melissa officinalis,Glycyrrhiza glabra
(COLISOLVE, Farmacia Legnani,
Milano, Italy), dosage not reported;
Pimpinella anisum, Glycyrrhiza glabra,
Forniculum vulgare, Ocimum
basilicum, Matricaria recutita
(VITABIOSA, Biosa Danmark,
Frederiksværk, Denmark), dosage not
reported; Boswellia serrata DE, Ficus
carica mother tincture; horse
colostrum; Mucosa compositum,
dosage not reported; indication not
reported
Warfarin (since 2 years)
Overanticoagulation INR 8;
Possible [4]
Unknown
and the causality relationship was defined as “probable.”
To our knowledge, these are the first reports of interaction
between warfarin and boswellia. The mechanism underlying
this interaction is unknown, but it has been recently
demonstrated that boswellic acids, assumed as the anti-
inflammatory principles of the Boswellia Species, are able
to inhibit lipoxygenase and directly interfere with COX-1
[14]. Cyclooxygenases inhibitor drugs (e.g., acetylsalicylic
acid) interact with warfarin provoking an increased risk
of bleeding, mainly as a result of platelet aggregation
inhibition, although not accompanied by a change in
INR. Furthermore, different species of boswellia (including
Boswellia serrata) could inhibit CYP2C19, CYP3A4, and CYP
2C9 [15], the most important isoenzyme metabolizing S-
warfarin, possibly increasing warfarin activity. It should be
also considered that genetic variants of the CYP2C9 may
contribute to an increase in the risk of overcoagulation due
to interaction INR increase (up to 8) was reported also in a
patient taking three multiherb products, including Boswellia
serrata. Some of the assumed herbs contain coumarin
derivates, but the high number of different plants made it
impossible to identify the interacting components. However,
multi-ingredient products should be strongly discouraged,
especially in patients taking anticoagulants, due to the high
risk of unknown toxicity and drug interactions by synergic
effects.
4. Discussion and Conclusions
Our analysis confirmed the risk of interactions between
herbs and VKAs, possibly exiting in adverse events [16].
Limited information about the pharmacokinetics, pharma-
codynamics, and manufacturing properties of herbal and
dietary supplements leads to difficulty in characterizing
and predicting interactions and understanding their mech-
anisms. Although the use of herbal products may not be
dangerous per se, lack of communication between patient
and physician might alter clinical management of adverse
events. Healthcare providers should be aware of potential
interactions and their role in patients’ education should be
active. Physicians should be encouraged to discuss com-
plementary/alternative therapies with their patients putting
an end to the “Do not ask! Do not tell!” approach that
characterized communication in this area. This is the first
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step to have the best approach to understand possible INR
alterations linked to herb-VKA interaction and to rightly
educate patients in treatment with VKA.
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